AI pharmaceutical company XtalPi secured USD 400 Million in a Series D financing round led by OrbiMed and RRJ, with investors including Sequoia Capital, Sino Biopharmecutical, and 5Y Capital participating in the deal.
The new funds come less than a year after the company raised USD 300 million in a Series C round and brings XtalPi’s valuation to over RMB 13 billion (USD 2 billion).
Company: XtalPi Inc.
Round: Series D
Funding Month: August 2021
Lead Investors: OrbiMed and RRJ
Additional Investors: Sequoia Capital, Sino Biopharmecutical, and 5Y Capital
Company Website: https://www.xtalpi.com/en/
Software Category: ID4 (Intelligent Digital Drug Discovery and Development) platform >AI
About the Company: XtalPi is an AI drug R&D company that uses computational physics, quantum chemistry, and cloud computing to provide intelligent drug development for pharmaceutical companies. The company’s ID4 (Intelligent Digital Drug Discovery and Development) platform can accurately predict the important characteristics for new drugs by measuring various chemical indicators, enhancing drug R&D efficiency. ID4 has enabled hundreds of pharmaceutical companies to accelerate their research pipelines, leading to dozens of discoveries.